BURBANK, Calif., April 26, 2006 (PRIMEZONE) -- Imaging3(tm), Inc, (OTCBB:IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today provided insight into one of the many health care sectors where it's new product, The Dominion(tm) is poised to usher in a revolutionary shift of the health care paradigm. The Dominion's real-time 3D imaging will provide relief for patients suffering from peripheral vascular disease (PVD), a health care specialty also sometimes referred to as peripheral arterial disease (PAD), or hardening of the arteries.
This disease occurs when the normal lining of the arteries deteriorates, the walls of arteries thicken, and deposits of fat and plaque build up, causing narrowing (or even blockage) of the arteries. Approximately 10 million Americans are affected by PVD each year. According to Millennium Research Group, a Toronto based medical research firm, the peripheral vascular device market was valued at nearly $1.5 billion and will increase at a compound annual growth rate of greater than 10% over the forecast period.
The aging U.S. population, combined with growing incidences of obesity, diabetes, and end stage renal disease will drive the demand for peripheral vascular procedures higher throughout the next decade. Demand has also been fueled by increased screening, detection and public awareness of PVD, as evidenced by growth in diagnostic procedures. Several key segments are driving growth in peripheral vascular device revenues, including abdominal aortic aneurysm (AAA) stent grafts, peripheral stents, and vena cava filters. As a result, U.S. peripheral vascular device revenues of $2.5 billion are expected to be generated in 2008.
Dean Janes, Imaging3's CEO, said, "Viewing the human body in 3D in real time, gives the physician the ability to more accurately diagnose and treat patients with peripheral vascular disease. The ability to guide catheters, and accurately place balloon catheters and position stents inside the patient's arteries is greatly increased with 3D real time visualization." This increased accuracy results in less collateral damage to internal tissues and promotes more rapid healing and fewer post procedure complications.
The Dominion(tm) with its breakthrough real time 3D imaging will give physicians greater accuracy and increase performance and speed while performing these procedures because unlike other existing technology, surgeons will not have to reposition equipment or reorient their imaging device, as they must with other equipment. The Dominion(tm) will display the vascular structures in three dimensions and in real time thus allowing the physician to guide their catheters and stents through out the twists and turns common for vascular tissue.
About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at www.imaging3.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.